CO6450684A2 - Derivado de amida - Google Patents

Derivado de amida

Info

Publication number
CO6450684A2
CO6450684A2 CO11136986A CO11136986A CO6450684A2 CO 6450684 A2 CO6450684 A2 CO 6450684A2 CO 11136986 A CO11136986 A CO 11136986A CO 11136986 A CO11136986 A CO 11136986A CO 6450684 A2 CO6450684 A2 CO 6450684A2
Authority
CO
Colombia
Prior art keywords
group
integer
alkyl group
substituted
independently selected
Prior art date
Application number
CO11136986A
Other languages
English (en)
Inventor
Takuya Ikeda
Takanori Yamazaki
Hiroshi Tsuchida
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CO6450684A2 publication Critical patent/CO6450684A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a uncompuesto o una sal farmacológicamente aceptable delmismo que tiene un excelente efecto antagonista sobre unreceptor de neurocinina NK1, un receptor de neurocininaNK2 y un receptor muscarínico M3, y es útil como un agenteterapéutico para asma bronquial, enfermedad pulmonarobstructiva crónica, o similares; se describe un compuestopresentado por la fórmula general (I):[en donde R1 representa un átomo de hidrógeno, un grupoalquilo de C1-C6, o similares; R2 representa un átomo dehidrógeno, un grupo alquilo de C1-C6, o similares; R3representa un grupo fenilo que puede ser sustituido con 1 a5 grupos seleccionados independientemente del gruposustituyente A, o similares; R4 representa un grupo feniloque puede ser sustituido con 1 a 5 grupos seleccionadosindependientemente del grupo sustituyente A, o similares;L1 representa un grupo alquileno de C1-C10, o similares; L2representa un grupo carbonilo, un grupo representado porla fórmula -N(R5)-C(=O)-, un grupo representado por lafórmula -C(=O)-N(R5)-, o similares; R5 representa un átomode hidrógeno, un grupo alquilo de C1-C6, o similares; Erepresenta un grupo fenileno que puede ser sustituido con1 a 4 grupos seleccionados independientemente del gruposustituyente A, o similares; m es un entero de 0 a 4; n esun entero de 0 a 4; p es un entero de 0 a 2; q es un enterode 1 a 10; r es 1 ó 2; s es ó 1; y el grupo sustituyente Arepresenta el grupo que consiste de un átomo de halógeno,un grupo alquilo de C1-C6, un grupo alquilo halogenado deC1-C6, o similares], o una sal farmacológicamenteaceptable del mismo.
CO11136986A 2009-03-17 2011-10-14 Derivado de amida CO6450684A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009065029 2009-03-17

Publications (1)

Publication Number Publication Date
CO6450684A2 true CO6450684A2 (es) 2012-05-31

Family

ID=42739647

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11136986A CO6450684A2 (es) 2009-03-17 2011-10-14 Derivado de amida

Country Status (17)

Country Link
US (1) US8476253B2 (es)
EP (1) EP2409977A4 (es)
JP (1) JPWO2010106988A1 (es)
KR (1) KR20110136813A (es)
CN (1) CN102439007A (es)
AU (1) AU2010225747A1 (es)
BR (1) BRPI1014125A2 (es)
CA (1) CA2755697A1 (es)
CO (1) CO6450684A2 (es)
IL (1) IL215153A0 (es)
MX (1) MX2011009700A (es)
NZ (1) NZ595723A (es)
RU (1) RU2011141794A (es)
SG (1) SG174389A1 (es)
TW (1) TW201036964A (es)
WO (1) WO2010106988A1 (es)
ZA (1) ZA201106792B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138916A1 (ja) * 2010-05-07 2011-11-10 第一三共株式会社 多環式化合物
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US8940726B2 (en) * 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CN110227164B (zh) 2018-03-06 2021-11-23 江苏吉贝尔药业股份有限公司 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用
CN115466254A (zh) * 2022-08-10 2022-12-13 安庆研至医药科技有限公司 一种抑制剂及其制备方法
US20240208997A1 (en) 2022-11-09 2024-06-27 Boehringer Ingelheim International Gmbh Cyclic benzimidazole derivatives as cgas inhibitors
WO2024099908A1 (en) 2022-11-09 2024-05-16 Boehringer Ingelheim International Gmbh Cyclic pyridine derivatives as cgas inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670048C3 (de) 1966-01-26 1980-09-04 C.H. Boehringer Sohn, 6507 Ingelheim Neue Norscopolaminderivate
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
DE4111243A1 (de) 1991-04-08 1992-10-15 Erbsloeh Julius & August In laengsrichtung allseitig geschlossene, unloesbare, feste profilverbindung
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
CN1154240A (zh) * 1995-11-06 1997-07-16 美国辉瑞有限公司 治疗癌症用的nk-1受体拮抗剂
NZ330198A (en) 1996-01-26 2000-06-23 Nattermann A & Cie Asthma therapeutic agents especially 2-phenyl-1,2-benzoisoselenazole-3(2H)-one
TR200002072T2 (tr) 1998-01-23 2000-12-21 Sankyo Company Limited Spiropiperidin türevleri
IL140622A0 (en) * 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
ATE259641T1 (de) 1999-07-23 2004-03-15 Banyu Pharma Co Ltd Amidderivate
EP1292281B1 (de) 2000-10-12 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG Neue tiotropium-haltige inhalationspulver
KR100599134B1 (ko) 2001-04-23 2006-07-12 에프. 호프만-라 로슈 아게 양성 전립선 비대증에 대한 ｎｋ-1 수용체 길항물질의 용도
AU2004209456A1 (en) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Quinoline-derived amide modulators of vanilloid VR1 receptor
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
PT1615699E (pt) 2003-04-15 2010-05-21 Merck Sharp & Dohme Moduladores benzoxazinil-amidociclopentil-heterocíclicos dos receptores de quemoquina
JP4853992B2 (ja) * 2004-02-25 2012-01-11 第一三共株式会社 インダノール誘導体
CA2557539A1 (en) 2004-02-25 2005-09-01 Sankyo Company Limited Indanol derivative
EP1723142A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
JP2007528408A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
JP2006160639A (ja) 2004-12-06 2006-06-22 Sankyo Co Ltd ニューロキニン受容体拮抗剤と抗コリン剤の併用
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7629336B2 (en) 2005-03-10 2009-12-08 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006138218A1 (en) 2005-06-13 2006-12-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007084530A (ja) * 2005-08-22 2007-04-05 Sankyo Co Ltd インダノール誘導体を含有する医薬組成物
JP5406039B2 (ja) 2006-12-21 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
WO2010007561A1 (en) * 2008-07-15 2010-01-21 Pfizer Limited Novel compounds active as muscarinic receptor antagonists

Also Published As

Publication number Publication date
CN102439007A (zh) 2012-05-02
TW201036964A (en) 2010-10-16
RU2011141794A (ru) 2013-04-27
JPWO2010106988A1 (ja) 2012-09-20
NZ595723A (en) 2012-10-26
BRPI1014125A2 (pt) 2016-04-12
CA2755697A1 (en) 2010-09-23
WO2010106988A1 (ja) 2010-09-23
US8476253B2 (en) 2013-07-02
SG174389A1 (en) 2011-10-28
MX2011009700A (es) 2011-12-08
EP2409977A4 (en) 2012-09-26
IL215153A0 (en) 2011-12-29
EP2409977A1 (en) 2012-01-25
KR20110136813A (ko) 2011-12-21
ZA201106792B (en) 2012-06-27
US20120071467A1 (en) 2012-03-22
AU2010225747A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
CO6450684A2 (es) Derivado de amida
CO6640247A2 (es) Compuesto[5.6]heterociclico o una sal farmacológicamente aceptable del mismo útil para la prevención de enfermedades asociadas con el metabolismo óseo
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
CL2008000212A1 (es) Compuestos derivados de fenotiazina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes, reducir los niveles de glucemia, adiccion a nicotina, adiccion al alcohol, trastornos del sistema nervioso central, entre
EA201171328A1 (ru) Производное замещенного изохинолина
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
UY30603A1 (es) Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica
AR065280A1 (es) Agentes antiparasitarios
GT200600339A (es) Inhibidores macrociclicos del virus de la hepatitis c
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
CO6150142A2 (es) Bezoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
AR087302A1 (es) Derivados aza heterociclicos sustituidos
BRPI0619894B8 (pt) composto de amina e composição farmacêutica
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR078321A1 (es) Derivados de 2,4'-bipiridina como inhibidores de cinasa (cdk9)
BR112015015275A8 (pt) composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso
AR047606A1 (es) 4-oxobenzonitrilos como moduladores de receptores de androgenos,composiciones farmaceuticas que los contienen y usos
CO6341610A2 (es) Compuesto heterociclilo aromatico que contiene nitrogeno.
GT200600017A (es) 4-feniltetrahidroisoquinolinas sustituidas, proceso para su preparacion, su uso como medicamento y medicamento que las comprende
RS51190B (sr) Aminoacilni derivati kao prolekovi i lekovi za lečenje tromboembolijskih bolesti
MX2009008028A (es) Agentes antiparasitarios.
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина

Legal Events

Date Code Title Description
FA Application withdrawn